- Home
- CTVA vs IQV Comparison
CTVA vs IQV Comparison
Compare CTVA & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CTVA
- IQV
- Stock Information
- Founded
- CTVA 2018
- IQV 1982
- Country
- CTVA United States
- IQV United States
- Employees
- CTVA N/A
- IQV N/A
- Industry
- CTVA Farming/Seeds/Milling
- IQV Biotechnology: Commercial Physical & Biological Resarch
- Sector
- CTVA Consumer Staples
- IQV Health Care
- Exchange
- CTVA Nasdaq
- IQV Nasdaq
- Market Cap
- CTVA 38.8B
- IQV 41.8B
- IPO Year
- CTVA N/A
- IQV 2013
- Fundamental
- Price
- CTVA $58.96
- IQV $233.95
- Analyst Decision
- CTVA Buy
- IQV Buy
- Analyst Count
- CTVA 21
- IQV 16
- Target Price
- CTVA $61.74
- IQV $267.87
- AVG Volume (30 Days)
- CTVA 2.7M
- IQV 957.9K
- Earning Date
- CTVA 11-06-2024
- IQV 10-31-2024
- Dividend Yield
- CTVA 1.15%
- IQV N/A
- EPS Growth
- CTVA N/A
- IQV 32.55
- EPS
- CTVA 1.27
- IQV 7.71
- Revenue
- CTVA $16,901,000,000.00
- IQV $15,155,000,000.00
- Revenue This Year
- CTVA $2.07
- IQV $4.30
- Revenue Next Year
- CTVA $4.15
- IQV $6.69
- P/E Ratio
- CTVA $46.59
- IQV $30.33
- Revenue Growth
- CTVA N/A
- IQV 3.23
- 52 Week Low
- CTVA $43.22
- IQV $167.42
- 52 Week High
- CTVA $59.13
- IQV $261.73
- Technical
- Relative Strength Index (RSI)
- CTVA 61.12
- IQV 49.63
- Support Level
- CTVA $56.45
- IQV $229.80
- Resistance Level
- CTVA $57.83
- IQV $237.34
- Average True Range (ATR)
- CTVA 0.87
- IQV 4.26
- MACD
- CTVA -0.00
- IQV 0.63
- Stochastic Oscillator
- CTVA 95.23
- IQV 73.78
About CTVA Corteva Inc.
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
About IQV IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.